Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon GloboCare Corp. (NASDAQ: ALBT) generates news across precision diagnostics, cellular therapy intellectual property, generative AI software, and commercial real estate. Company press releases describe Avalon as a commercial‑stage developer of precision diagnostic consumer products, with a flagship focus on the KetoAir™ handheld breathalyzer for ketogenic health management. News coverage frequently highlights deployments of KetoAir™ in wellness initiatives, first responder programs, and international online sales channels.
Investors following ALBT news will see updates on distribution agreements, affiliate marketing programs, and partnerships that incorporate KetoAir™ as a real‑time metabolic monitoring tool. Recent announcements include collaborations with Saga Health Corporation and SpecialtyHealth, Inc. for first responder wellness programs, as well as expansion of KetoAir™ availability into the United Kingdom through online sales. Avalon also reports on its co‑development agreement with Qi Diagnostics Limited to create a VOC nanosensor‑based cannabis breathalyzer aimed at supporting detection of potential cannabis‑impaired driving.
Beyond diagnostics, Avalon’s news flow includes developments in its cellular therapy intellectual property portfolio, such as the issuance of a Hong Kong patent for proprietary CAR‑T and CAR‑NK cell technology co‑developed with Arbele Limited. The company also issues updates on its acquisition of RPM Interactive, Inc. and the Catch‑Up generative AI SaaS platform, which is designed to automate short‑form video creation and support marketing for KetoAir™ and other consumer health products.
Regulatory and corporate actions also feature in ALBT news, including SEC filings, financing transactions, Nasdaq listing compliance updates, and progress on the proposed merger with YOOV Group Holding Limited. Readers can use this news stream to monitor how Avalon’s precision diagnostics, AI‑driven software, cellular therapy IP, and capital markets activities evolve over time.
Avalon GloboCare Corp. (NASDAQ: ALBT) announced the issuance of U.S. Patent No. 11,555,060 by the USPTO, covering the QTY Code, a breakthrough technology transforming water-insoluble proteins into soluble forms. This patent strengthens Avalon's intellectual property in immuno-oncology and cellular therapies, enhancing its competitive edge. The QTY platform has significant potential for applications, including addressing cytokine storms from COVID-19 and improving CAR T-cell therapies. Avalon has filed 16 joint patent applications with prestigious partners like MIT and aims to lead in innovative biotechnology solutions.
Avalon GloboCare Corp. (NASDAQ: ALBT) announced the appointment of Lourdes Felix to its Board of Directors, effective January 11, 2023. Felix, an experienced entrepreneur and corporate finance executive, has over 30 years in capital markets and public accounting. She is the CEO and CFO of BioCorRx Inc., where she has led significant capital procurement and business restructuring in the addiction treatment sector. Avalon aims to leverage her expertise to implement a roll-up strategy targeting toxicology labs within the addiction market, enhancing corporate governance and growth prospects.
Avalon GloboCare Corp. (NASDAQ: ALBT) announced a breakthrough in leukemia patient management through a newly developed fusion gene map technology. This advancement aims to create companion diagnostic kits to improve personalized treatment options. With a database from over 1,000 leukemia patients, significant unknown fusion genes were identified that may serve as diagnostic and therapeutic targets. The first diagnostic prototype is set to enter clinical studies by Q3 2023, enhancing Avalon's R&D pipeline and IP portfolio.
Avalon GloboCare Corp. (NASDAQ: ALBT) announced the completion of a $4 million private placement of Series A preferred stock with Chairman Daniel Lu. This funding, along with a previous $5 million placement, aims to finance the acquisition of Laboratory Services MSO, LLC. The acquisition is expected to close within 30 days and will enhance Avalon’s revenue and cash flow. The preferred stock is convertible into common stock at $1.00 or 90% of the closing price. An additional $6 million is planned through further stock sales for the acquisition's completion.
Avalon GloboCare Corp. (NASDAQ: ALBT) announces the discontinuation of its operations in China, maintaining only a small administrative office. The decision aims to reduce cash burn and refocus on U.S. markets alongside a transformative acquisition of Laboratory Services MSO, LLC, expected to boost earnings and provide clinical synergies. Shareholders are encouraged to vote in the upcoming annual meeting scheduled for December 29, 2022, addressing board composition and auditor ratification. This strategic shift reflects Avalon’s commitment to enhancing shareholder value and operational efficiency.
Avalon GloboCare Corp. will change its NASDAQ ticker symbol from AVCO to ALBT, effective November 10, 2022. This change reflects the company's new focus on laboratory services and biotherapeutics. Following a recent acquisition of Laboratory Services MSO, Avalon aims to enhance its revenue and create synergies within its existing operations. The acquisition is expected to significantly boost earnings and leverage its cellular therapy programs. Shareholders will not need to take any action regarding this symbol change.